Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 14, 2011
Reporting Period: Specific event date of October 14, 2011, with related events extending to October 20, 2011.
Key Financial Metrics
This filing is a Current Report (Form 8-K) detailing specific corporate events and agreements. It does not contain financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Agreements
- Termination of Existing Agreement: On October 14, 2011, the Company entered into an amendment to its Distribution Agreement with ID Biomedical Corporation of Quebec (IDB) regarding the Fluviral Influenza Vaccine. This amendment terminates the agreement solely for the 2012/2013 Flu Season. The original agreement will automatically terminate at the conclusion of the 2011/2012 Flu Season.
- New Distribution Arrangement: The Company entered into a new distribution agreement on October 20, 2011, with an unnamed manufacturer to distribute influenza vaccine for the 2012/2013 flu season.
- Terms of New Agreement: The new agreement covers the period from January 1, 2012, to December 31, 2012, with an option to renew for one year upon mutual agreement. Pricing is volume-based, and the Company will notify the manufacturer of required volumes in advance of the flu season.
Guidance, Outlook, and Risks
Outlook: The Company has secured alternative supply arrangements for the 2012/2013 flu season following the termination of the IDB agreement for that specific period.
Risks and Contingencies: The filing does not explicitly detail financial risks or contingencies beyond the operational shift in vaccine distribution partners. The transition relies on the successful execution of the new volume-based pricing agreement.
Key Facts for Investor Verification
- Confirmation that the ID Biomedical distribution agreement is strictly terminated for the 2012/2013 season only.
- Identification of the new manufacturer entered into the October 20, 2011 agreement.
- Verification of the volume commitments and pricing structure under the new 2012/2013 distribution agreement.
- Assessment of any potential supply chain disruptions during the transition between the 2011/2012 and 2012/2013 flu seasons.